ICU Medical (ICUI) Updates FY18 Earnings Guidance

ICU Medical (NASDAQ:ICUI) updated its FY18 earnings guidance on Thursday. The company provided earnings per share guidance of $8.45-8.85 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $8.60. ICU Medical also updated its FY 2018 guidance to $8.45-8.85 EPS.

A number of brokerages recently issued reports on ICUI. Zacks Investment Research lowered shares of ICU Medical from a strong-buy rating to a hold rating in a report on Thursday, October 11th. ValuEngine lowered shares of ICU Medical from a strong-buy rating to a buy rating in a report on Friday, August 3rd. BidaskClub lowered shares of ICU Medical from a strong-buy rating to a buy rating in a report on Thursday, September 20th. Finally, TheStreet raised shares of ICU Medical from a c+ rating to a b+ rating in a report on Monday, August 20th.

Shares of ICUI traded down $28.23 during mid-day trading on Friday, reaching $232.01. The stock had a trading volume of 695,340 shares, compared to its average volume of 163,883. ICU Medical has a 52-week low of $196.33 and a 52-week high of $321.70. The firm has a market capitalization of $5.28 billion, a P/E ratio of 42.03 and a beta of 0.65.

ICU Medical (NASDAQ:ICUI) last announced its quarterly earnings data on Thursday, November 8th. The medical instruments supplier reported $1.85 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.51 by $0.34. ICU Medical had a net margin of 5.93% and a return on equity of 12.78%. The firm had revenue of $327.20 million during the quarter, compared to analyst estimates of $334.97 million. During the same quarter in the prior year, the firm posted $1.12 earnings per share. ICU Medical’s quarterly revenue was down 4.7% on a year-over-year basis. As a group, equities analysts anticipate that ICU Medical will post 7.6 EPS for the current year.

In other ICU Medical news, Director Pfizer Inc sold 700,000 shares of the stock in a transaction dated Monday, August 13th. The shares were sold at an average price of $284.35, for a total transaction of $199,045,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Virginia Ruth Sanzone sold 787 shares of the stock in a transaction dated Tuesday, August 28th. The stock was sold at an average price of $303.12, for a total transaction of $238,555.44. Following the transaction, the vice president now directly owns 1,367 shares of the company’s stock, valued at approximately $414,365.04. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 711,920 shares of company stock valued at $202,651,956. 12.50% of the stock is currently owned by insiders.

ILLEGAL ACTIVITY NOTICE: “ICU Medical (ICUI) Updates FY18 Earnings Guidance” was published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this report on another site, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this report can be viewed at https://sportsperspectives.com/2018/11/09/icu-medical-icui-updates-fy18-earnings-guidance.html.

About ICU Medical

ICU Medical, Inc develops, manufactures, and sells medical devices used in vascular therapy, critical care, and oncology applications worldwide. It offers infusion therapy products comprising a tube running from a bottle or plastic bag containing a solution to a catheter inserted in a patient's vein.

Recommended Story: What is a Reverse Stock Split?

Receive News & Ratings for ICU Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply